Wolf Theiss advises Indutrade on the acquisition of Sinmed

Warsaw, 23 October 2026 – Wolf Theiss acted as lead counsel to Indutrade, an international technology and industrial group, on the acquisition of 100% of the shares in Sinmed, a Polish medical equipment company. The acquisition further strengthens Indutrade’s position in the Polish healthcare sector.

Indutrade has signed an agreement to acquire 100% of the shares in Sinmed Sp. z o.o., a Polish medical equipment company with annual sales of approximately PLN 50 million. Completion of the transaction is subject to approval by the Polish competition authority and is expected in Q4 2026. Following completion of the transaction, Sinmed will become part of Indutrade’s Business Area Life Science.

Sinmed is a technical trading company specialising in single-use products and medical consumables. The company has a diverse customer base, including hospitals, universities, healthcare providers and medical technology distribution companies. Sinmed has a strong position in its niche, long-term partnerships and favourable conditions for continued sustainable and profitable growth.

Wolf Theiss acted as lead counsel to Indutrade, providing legal advice throughout all stages of the acquisition process.

The Wolf Theiss team was led by Partners Izabela Zielińska-Barłożek and Maciej A. Szewczyk, supported by Senior Associate Sylwia Staleńczyk-Janc and Associate Jan Kaźmierczak (all Corporate/M&A). The team also included Counsels Joanna Jagiełło (Life Sciences), Michał Derdak (Competition & Antitrust), Marcin Żak (Real Estate), Iwona Huryn (Real Estate) and Adrian Krzyżanowski (Banking & Finance), Associates Adam Michnowski (Corporate M&A), Paulina Buczek (Environment), Oliwia Pecht (Employment), Julia Zuzanna Biedrzycka (IP & TMT) and Kinga Kluszczyńska (IP & TMT).